arrow
R

Ramin Alipour

peter maccallum cancer center
H指数:16
被引数:958

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

[177Lu]Lu-PSMA-617 in combination with pembrolizumab for treatment of metastatic castration resistant prostate cancer (PRINCE): a single-arm, phase 1b/2 study

[177Lu]Lu-PSMA-617与pembrolizumab联合治疗转移性去势抵抗性前列腺癌(PRINCE):一项单臂、1b/2期研究

2026-03-300
OAAI
Prognostic Value of Initial Imaging and PSA Change with [177Lu]Lu-PSMA-617 Radiopharmaceutical Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer: A ProsTIC Registry Analysis

转移性去势抵抗性前列腺癌患者中初始影像和PSA变化对[177Lu]Lu-PSMA-617放射性药物治疗的预后价值:一项ProsTIC登记研究分析

2025-12-011
PRE
Deep Learning for Automated Measures of SUV and Molecular Tumor Volume in [68Ga]PSMA-11 or [18F]DCFPyL, [18F]FDG, and [177Lu]Lu-PSMA-617 Imaging with Global Threshold Regional Consensus Network
2025-11-010
PRE
MULTI-SITE, PROSPECTIVE TRIAL EVALUATING FET-PET IN GLIOBLASTOMA (FIG) STUDY (TROG 18.06): CENTRAL NUCLEAR MEDICINE AND RADIATION ONCOLOGY REVIEW OF FET-PET BIOLOGIC TARGET VOLUME DELINEATION FOR RADIATION PLANNING

多中心前瞻性试验评估胶质母细胞瘤中FET-PET的应用(FIG研究,TROG 18.06):中心核医学与放射肿瘤学对放射治疗计划中FET-PET生物靶区勾画的审查

2025-11-010
OAAI
Lutetium-177 [177Lu]Lu-PSMA-I&T plus radium-223 in patients with metastatic castration-resistant prostate cancer (AlphaBet): an interim analysis of the investigator-initiated, single-centre, single-arm, phase 1/2 trial

镥-177 [177Lu]Lu-PSMA-I&T 联合镭-223 治疗转移性去势抵抗性前列腺癌(AlphaBet 研究):一项研究者发起、单中心、单臂、Ⅰ/Ⅱ期试验的期中分析

2025-10-180
PRE
First-in-human results of terbium-161 [161Tb]Tb-PSMA-I&T dual beta–Auger radioligand therapy in patients with metastatic castration-resistant prostate cancer (VIOLET): a single-centre, single-arm, phase 1/2 study

钽-161 [161Tb]Tb-PSMA-I&T双β–Auger放射性配体疗法在转移性去势抵抗性前列腺癌患者中的首次人体研究结果(VIOLET):一项单中心、单臂、I/II期研究

2025-07-030
PRE
Prevalence and Medium-Term Outcomes of Patients with Biopsy-Proven Intermediate-to High-Risk Prostate Adenocarcinoma with Low Intraprostatic Uptake on [68Ga]Ga-PSMA-11 PET/CT in the proPSMA Study

在中位随访期研究中,[68Ga]Ga-PSMA-11 PET/CT检查显示前列腺腺癌活检证实的中危至高危患者体内低度摄取的患病率及中期结局

2025-03-270
PRE
Safety and efficacy of re-treatment with [177Lu]Lu-DOTA-Octreotate radionuclide therapy in progressive gastro-entero-pancreatic neuroendocrine tumours - a single centre experience

[177Lu]Lu-DOTA-奥曲肽放射性核素疗法在进展性胃肠胰神经内分泌肿瘤中重复治疗的 safety 和 efficacy:一项单中心经验

2025-03-260
OA
MULTI-SITE, PROSPECTIVE TRIAL EVALUATING FET-PET IN GLIOBLASTOMA (FIG) STUDY (TROG 18.06): PRELIMINARY RESULTS OF CENTRAL NUCLEAR MEDICINE REVIEW OF FET-PET BIOLOGIC TARGET VOLUME DELINEATION FOR RADIATION PLANNING
2024-11-110
PRE
Prostate cancer working group 4 (PCWG4) preliminary criteria using serial PSMA PET/CT for response evaluation: Analysis from the PRINCE trial

前列腺癌工作组4 (PCWG4) 使用连续PSMA PET/CT进行疗效评估的初步标准:PRINCE试验分析

2024-09-011
PRE
Clinical Trial Protocol for VIOLET: A Single-Center, Phase I/II Trial Evaluation of Radioligand Treatment in Patients with Metastatic Castration-Resistant Prostate Cancer with [161Tb]Tb-PSMA-I&T 161 Tb]Tb-PSMA-I&T

VIOLET的临床试验方案: [161 Tb] tb-psma-i & T转移性去势抵抗性前列腺癌患者放射配体治疗的单中心I/II期试验评估

2024-07-111
PRE
Delineation and agreement of FET PET biological volumes in glioblastoma: results of the nuclear medicine credentialing program from the prospective, multi-centre trial evaluating FET PET In Glioblastoma (FIG) study-TROG 18.06

胶质母细胞瘤中FET PET生物体积的描述和一致性: 来自评估胶质母细胞瘤中FET PET的前瞻性多中心试验 (FIG) 研究-TROG 18.06的核医学认证计划的结果

2023-08-119
OAAI